Research
Hormonal
Alternative splicing of the p53 gene produces the p44 variant, which accelerates aging phenotypes, cognitive decline, and senescence by hyperactivating the IGF-1 pathway.
Current research focuses on molecular mechanisms; no direct human intervention is recommended based solely on this paper.
GoodSupportsHIGH confidence
overexpression of p44 in transgenic mice (p44+/+) leads to an accelerated age-associated phenotype, suppresses cell proliferation, and increases senescence... p44+/+ transgenic mice also display premature synaptic deficit, cognitive decline as well as Alzheimer’s disease-like features
Why this rating
Supported by transgenic mouse models (Maier et al., 2004; Pehar et al., 2010, 2014).
Source
The emerging role of alternative splicing in senescence and aging
Mathieu Deschênes et al. · Aging Cell · 2017
DOI 10.1111/acel.12646
narrative_reviewCited 169×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The accumulation of senescent cells in tissues drives organ degeneration and aging phenotypes, and their clearance extends lifespan and improves homeostasis in mammalian models.Good
- Progeria (HGPS) is caused by a splicing mutation in the LMNA gene producing progerin, which sequesters in the nuclear membrane and reduces SIRT1 activity, modeling vascular aging.Good
- The splicing factor SFA-1 (SF1 homolog) promotes longevity in C. elegans, and its depletion compromises the longevity benefits of caloric restriction.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →